Filing Details

Accession Number:
0001179110-15-003033
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-02-20 15:02:49
Reporting Period:
2015-02-18
Filing Date:
2015-02-20
Accepted Time:
2015-02-20 15:02:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1235010 Momenta Pharmaceuticals Inc MNTA Biological Products, (No Disgnostic Substances) (2836) 043561634
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1427944 M. James Roach C/O Momenta Pharmaceuticals, Inc.
675 West Kendall Street
Cambridge MA 02142
Senior Vp, Development And Chi No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-02-18 20,748 $0.00 122,711 No 4 A Direct
Common Stock Disposition 2015-02-18 252 $11.91 122,459 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2015-02-18 41,498 $13.02 41,498 $13.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
352,413 2015-05-18 2025-02-18 No 4 A Direct
Footnotes
  1. Represents 20,748shares of restricted common stock, $0.0001 par value per share, awarded pursuant to the Company's 2013 Stock Incentive Plan, and subject to a restricted stock agreement to be entered between the Company and Mr. Roach. Pursuant to the restricted stock agreement, 25% of the shares of restricted Common Stock shall vest on February 18, 2016 and an additional 6.25% of the shares of restricted Common Stock shall vest at the end of each three-month period thereafter.
  2. Represents an option granted by the issuer pursuant to the issuer's 2013 Stock Incentive Plan. Subject to certain criteria, the shares subject to such option vest as to 6.25% of the shares at the end of each three-month period following the grant date.
  3. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2009.